Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation

Science Translational Medicine

Volumn 7, Issue 303, 2015, Pages

  Spence, Shaun ^a   Greene, Michelle K ^b   Fay, François ^b,c   Hams, Emily ^d   Saunders, Sean P ^d   Hamid, Umar ^a   Fitzgerald, Marianne ^a   Beck, Jonathan ^a   Bains, Baljinder K ^b   Smyth, Peter ^b   Themistou, Efrosyni ^b   Small, Donna M ^a   Schmid, Daniela ^b   O'Kane, Cecilia M ^a   Fitzgerald, Denise C ^a   Abdelghany, Sharif M ^b,e   Johnston, James A ^a,f   Fallon, Padraic G ^d,g   Burrows, James F ^b   McAuley, Daniel F ^a   Kissenpfennig, Adrien ^a   Scott, Christopher J ^b   more..

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d TRINITY COLLEGE DUBLIN   (Ireland)

^e UNIVERSITY OF JORDAN   (Jordan)

^f AMGEN INC   (United States)

^g OUR LADY S CHILDREN S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; DI(ALPHA2-8) N ACETYLNEURAMINIC ACID NANOPARTICLE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIGAND; LIPOPOLYSACCHARIDE; POLYGLACTIN; RECEPTOR; SIALIC ACID; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; SIGLEC E; SIGLEC E RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; N ACETYLNEURAMINIC ACID; NANOPARTICLE;

ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LUNG INJURY; LUNG PERFUSION; MACROPHAGE; MALE; MONOCYTE; MOUSE; NONHUMAN; OLIGOMERIZATION; PHARMACOLOGICAL BLOCKING; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SEPSIS; UPREGULATION; ANIMAL; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; METABOLISM; PHYSIOLOGY;

ANIMALS; HUMANS; INFLAMMATION; INTERLEUKIN-10; MICE; MICE, INBRED C57BL; N-ACETYLNEURAMINIC ACID; NANOPARTICLES; SIALIC ACID BINDING IMMUNOGLOBULIN-LIKE LECTINS; UP-REGULATION;

EID: 84940825485     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aab3459     Document Type: Article

References (53)

1. M. Singer, Biomarkers in sepsis. Curr. Opin. Pulm. Med. 19, 305-309 (2013).
2. P. E. Marik, Early management of severe sepsis: Concepts and controversies. Chest 145, 1407-1418 (2014).
3. C. Brun-Buisson, C. Minelli, G. Bertolini, L. Brazzi, J. Pimentel, K. Lewandowski, J. Bion, J.-A. Romand, J. Villar, A. Thorsteinsson, P. Damas, A. Armaganidis, F. Lemaire; ALIVE Study Group, Epidemiology and outcome of acute lung injury in European intensive care units. Intensive Care Med. 30, 51-61 (2004).
4. D. F. McAuley, J. G. Laffey, C. M. O'Kane, G. D. Perkins, B. Mullan, T. J. Trinder, P. Johnston, P. A. Hopkins, A. J. Johnston, C. McDowell, C. McNally; HARP-2 Investigators; Irish Critical Care Trials Group, Simvastatin in the acute respiratory distress syndrome. N. Engl. J. Med. 371, 1695-1703 (2014).
5. T. Kawai, S. Akira, TLR signaling. Semin. Immunol. 19, 24-32 (2007).
6. M. Ando, W. Tu, K.-i. Nishijima, S. Iijima, Siglec-9 enhances IL-10 production in macrophages via tyrosine-based motifs. Biochem. Biophys. Res. Commun. 369, 878-883 (2008).
7. D. Y. Mason, H. Stein, J. Gerdes, K. A. Pulford, E. Ralfkiaer, B. Falini, W. N. Erber, K. Micklem, K. C Gatter, Value of monoclonal anti-CD22 (p135) antibodies for the detection of normal and neoplastic B lymphoid cells. Blood 69, 836-840 (1987).
8. P. R. Crocker, Siglecs in innate immunity. Curr. Opin. Pharmacol. 5, 431-437 (2005).
9. M. K. O'Reilly, J. C. Paulson, Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol. Sci. 30, 240-248 (2009).
10. S. J. McMillan, R. S. Sharma, E. J. McKenzie, H. E. Richards, J. Zhang, A. Prescott, P. R. Crocker, Siglec-E is a negative regulator of acute pulmonary neutrophil inflammation and suppresses CD11b [32-integrin-dependent signaling. Blood 121, 2084-2094 (2013).
11. C. R. Boyd, S.J. Orr, S.Spence, J. F. Burrows, J. Elliott, H. P. Carroll, K. Brennan, J. Ní Gabhann, W. A. Coulter, C. Jones, P. R. Crocker, J. A. Johnston, C. A. Jefferies, Siglec-E is up-regulated and phosphorylated following lipopolysaccharide stimulation in order to limit TLR-driven cytokine production. J. Immunol. 183, 7703-7709 (2009).
12. S. Mizrahi, B. F. Gibbs, L. Karra, M. Ben-Zimra, F. Levi-Schaffer, Siglec-7 is an inhibitory receptor on human mast cells and basophils. J. Allergy Clin. Immunol. 134, 230-233 (2014).
13. K. Miyazaki, K. Sakuma, Y. I. Kawamura, M. Izawa, K. Ohmori, M. Mitsuki, T. Yamaji, Y. Hashimoto, A. Suzuki, Y. Saito, T. Dohi, R. Kannagi, Colonic epithelial cells express specific ligands for mucosal macrophage immunosuppressive receptors siglec-7 and-9. J. Immunol. 188, 4690-4700 (2012).
14. L. Nitschke, H. Floyd, P. R. Crocker, New functions for the sialic acid-binding adhesion molecule CD22, a member of the growing family of Siglecs. Scand. J. Immunol. 53, 227-234 (2001).
15. E. C. M. Brinkman-Van der Linden, A. Varki, New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope. J. Biol. Chem. 275, 8625-8632 (2000).
16. C. J. Scott, W. M. Marouf, D. J. Quinn, R. J. Buick, S. J. Orr, R. F. Donnelly, P. A. McCarron, Immunocolloidal targeting of the endocytotic siglec-7 receptor using peripheral attachment of siglec-7 antibodies to poly(lactide-co-glycolide) nanoparticles. Pharm. Res. 25, 135-146 (2008).
17. C. Jandus, H. U. Simon, S. von Gunten, Targeting Siglecs-A novel pharmacological strategy for immuno-and glycotherapy. Biochem. Pharmacol. 82, 323-332 (2011).
18. C. S. Fuchs, M. Fakih, L. Schwartzberg, A. L. Cohn, L. Yee, L Dreisbach, M. F. Kozloff, Y.j. Hei, F. Galimi, Y. Pan, V. Haddad, C.-P. Hsu, A. Sabin, L. Saltz, TRAIL receptor agonist conatu-mumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial. Cancer 119, 4290-4298 (2013).
19. P. A. McCarron, R. F. Donnelly, W. M. Marouf, Celecoxib-loaded poly(D, L-lactide-co-glyco-lide) nanoparticles prepared using a novel and controllable combination of diffusion and emulsification steps as part of the salting-out procedure. J. Microencapsul. 23, 480-498 (2006).
20. B. Sulzer, R. J. De Boer, A. S. Perelson, Cross-linking reconsidered: Binding and cross-linking fields and the cellular response. Biophys. J. 70, 1154-1168 (1996).
21. B. D. Harms, J. D. Kearns, S. Iadevaia, A. A. Lugovskoy, Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies. Methods 65, 95-104 (2014).
22. J. E. Juskewitch, J. L. Platt, B. E. Knudsen, K. L. Knutson, G. J. Brunn, J. P. Grande, Disparate roles of marrow-and parenchymal cell-derived TLR4 signaling in murine LPS-induced systemic inflammation. Sci. Rep. 2, 918 (2012).
23. J.D.Veltman, M.E.H.Lambers, M.vanNimwegen, R.W.Hendriks, H.CHoogsteden, J.P.J.J.Hegmans, J. G. J. V. Aerts, Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. Br. J. Cancer 103, 629-641 (2010).
24. D. Rittirsch, M. S. Huber-Lang, M. A. Flierl, P. A. Ward, Immunodesign of experimental sepsis by cecal ligation and puncture. Nat. Protoc. 4, 31-36 (2009).
25. E. Hams, S. P. Saunders, E. P. Cummins, A. O'Connor, M. T. Tambuwala, W. M. Gallagher, A. Byrne, A. Campos-Torres, P. M. Moynagh, C. Jobin, C T. Taylor, P. G. Fallon, The hydroxylase inhibitor DMOG attenuates endotoxic shock via alternative activation of macrophages and IL-10 production by B1 cells. Shock 36, 295-302 (2011).
26. G. Matute-Bello, C. W. Frevert, T. R. Martin, Animal models of acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 295, L379-L399 (2008).
27. J. A. Bastarache, T. S. Blackwell, Development of animal models for the acute respiratory distress syndrome. Dis. Model. Mech. 2, 218-223 (2009).
28. L. K. Reiss, U. Uhlig, S. Uhlig, Models and mechanisms of acute lung injury caused by direct insults. Eur. J. Cell Biol. 91, 590-601 (2012).
29. N. Matsuda, Y. Hattori, S. Jesmin, S. Gando, Nuclear factor-KB decoy oligodeoxynucleotides prevent acute lung injury in mice with cecal ligation and puncture-induced sepsis. Mol. Pharmacol. 67, 1018-1025 (2005).
30. L. Zhang, S. Jin, C. Wang, R. Jiang, J. Wan, Histone deacetylase inhibitors attenuate acute lung injury during cecal ligation and puncture-induced polymicrobial sepsis. World J. Surg. 34, 1676-1683 (2010).
31. H. Björkbacka, K. A. Fitzgerald, F. Huet, X. Li, J. A. Gregory, M. A. Lee, C. M. Ordija, N. E. Dowley, D. T. Golenbock, M. W. Freeman, The induction of macrophage gene expression by LPS predominantly utilizes Myd88-independent signaling cascades. Physiol. Genomics 19, 319-330 (2004).
32. J. W. Lee, X. Fang, N. Gupta, V. Serikov, M. A. Matthay, Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc. Natl. Acad. Sci. U.S.A. 106, 16357-16362 (2009).
33. J. W. Lee, A. Krasnodembskaya, D. H. McKenna, Y. Song, J. Abbott, M. A. Matthay, Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am. J. Respir. Crit. Care Med. 187, 751-760 (2013).
34. D. F. McAuley, G. F. Curley, U. I. Hamid, J. G. Laffey, J. Abbott, D. H. McKenna, X. Fang, M. A. Matthay, J. W. Lee, Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation. Am. J. Physiol. Lung Cell. Mol. Physiol. 306, L809-L815 (2014).
35. F. Fay, K. M. McLaughlin, D. M. Small, D. A. Fennell, P. G. Johnston, D. B. Longley, C. J. Scott, Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery. Biomaterials 32, 8645-8653 (2011).
36. P. A. McCarron, W. M. Marouf, D. J. Quinn, F. Fay, R. E. Burden, S. A. Olwill, C. J. Scott, Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells. Bioconjug. Chem. 19, 1561-1569 (2008).
37. S. M. Abdelghany, D. Schmid, J. Deacon, J. Jaworski, F. Fay, K. M. McLaughlin, J. A. Gormley, J. F. Burrows, D. B. Longley, R. F. Donnelly, C. J. Scott, Enhanced antitumor activity of the photosensitizer meso-tetra(N-methyl-4-pyridyl) porphine tetra tosylate through encapsulation in antibody-targeted chitosan/alginate nanoparticles. Biomacromolecules 14, 302-310 (2013).
38. D. Schmid, F. Fay, D. M. Small, J. Jaworski, J. S. Riley, D. Tegazzini, C. Fenning, D. S. Jones, P. G. Johnston, D. B. Longley, C. J. Scott, Efficient drug delivery and induction of apopto-sis in colorectal tumors using a death receptor 5-targeted nanomedicine. Mol. Ther. 22, 2083-2092 (2014).
39. J. Q. Zhang, B. Biedermann, L. Nitschke, P. R. Crocker, The murine inhibitory receptor mSiglec-E is expressed broadly on cells of the innate immune system whereas mSiglec-F is restricted to eosinophils. Eur. J. Immunol. 34, 1175-1184 (2004).
40. G. F. Weber, B. G. Chousterman, S. He, A. M. Fenn, M. Nairz, A. Anzai, T. Brenner, F. Uhle, Y. Iwamoto, C. S. Robbins, L. Noiret, S. L. Maier, T. Zönnchen, N. N. Rahbari, S. Schölch, A. Klotzsche-von Ameln, T. Chavakis, J. Weitz, S. Hofer, M. A. Weigand, M. Nahrendorf, R. Weissleder, F. K. Swirski, Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis. Science 347, 1260-1265 (2015).
41. K. Lock, J. Zhang, J. Lu, S. H. Lee, P. R. Crocker, Expression of CD33-related siglecs on human mononuclear phagocytes, monocyte-derived dendritic cells and plasmacytoid dendritic cells. Immunobiology 209, 199-207 (2004).
42. A. Mantovani, F. Marchesi, IL-10 and macrophages orchestrate gut homeostasis. Immunity 40, 637-639 (2014).
43. G.-Y. Chen, X. Chen, S. King, K. A. Cavassani, J. Cheng, X. Zheng, H. Cao, H. Yu, J. Qu, D. Fang, W. Wu, X.-F. Bai, J. Q. Liu, S. A. Woodiga, C. Chen, L. Sun, C. M. Hogaboam, S. L. Kunkel, P. Zheng, Y. Liu, Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction. Nat. Biotechnol. 29, 428-435 (2011).
44. H. Läubli, O. M. T. Pearce, F. Schwarz, S. S. Siddiqui, L. Deng, M. A. Stanczak, L. Deng, A. Verhagen, P. Secrest, C. Lusk, A. G. Schwartz, N. M. Varki, J. D. Bui, A. Varki, Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proc. Natl. Acad. Sci. U.S.A. 111, 14211-14216 (2014).
45. A. F. Carlin, S. Uchiyama, Y.-C. Chang, A. L. Lewis, V. Nizet, A. Varki, Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response. Blood 113, 3333-3336 (2009).
46. B. Khatua, S. Roy, C. Mandal, Sialic acids siglec interaction: A unique strategy to circumvent innate immune response by pathogens. Indian J. Med. Res. 138, 648-662 (2013).
47. W. C. Chen, G. C. Completo, D. S. Sigal, P. R. Crocker, A. Saven, J. C. Paulson, In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood 115, 4778-4786 (2010).
48. W. C. Chen, D. S. Sigal, A. Saven, J. C. Paulson, Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22. Leuk. Lymphoma 53, 208-210 (2012).
49. L. Bondioli, L. Costantino, A. Ballestrazzi, D. Lucchesi, D. Boraschi, F. Pellati, S. Benvenuti, G. Tosi, M. A. Vandelli, PLGA nanoparticles surface decorated with the sialic acid, N-acetylneuraminic acid. Biomaterials 31, 3395-3403 (2010).
50. G. Tosi, A. V. Vergoni, B. Ruozi, L. Bondioli, L. Badiali, F. Rivasi, L. Costantino, F. Forni, M. A. Vandelli, Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution. J. Control. Release 145, 49-57 (2010).
51. N. Kawasaki, C. D. Rillahan, T.-Y. Cheng, I. Van Rhijn, M. S. Macauley, D. B. Moody, J. C. Paulson, Targeted delivery of mycobacterial antigens to human dendritic cells via Siglec-7 induces robust T cell activation. J. Immunol. 193, 1560-1566 (2014).
52. W. C. Chen, N. Kawasaki, C. M. Nycholat, S. Han, J. Pilotte, P. R. Crocker, J. C. Paulson, Antigen delivery to macrophages using liposomal nanoparticles targeting sialoadhesin/CD169. PLOS One 7, e39039 (2012).
53. R. Kühn, J. Löhler, D. Rennick, K. Rajewsky, W. Müller, Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75, 263-274 (1993).